Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous Ocrevus in patients with multiple sclerosis
2023-505975-54-00Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Roche. Primary endpoint: Serum ocrelizumab AUC from Day 1 to Week 12. Started Jun 2024; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2023-505975-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505975-54-00.